Looks like you’re on the UK site. Choose another location to see content specific to your location
Pfizer licenses antifungal therapy Cresemba from Basilea in Europe
Pfizer has completed a licensing agreement that will provide the company with commercialisation rights to a novel antifungal treatment.
The deal with Basilea Pharmaceutica sees Pfizer obtain the exclusive rights in Europe to Cresemba, a treatment for adult patients with diagnosed invasive aspergillosis and mucormycosis.
Both of these conditions are serious forms of infection associated with high morbidity and mortality among immunocompromised patients. Cresemba has been approved as a therapy for these indications in the US and Europe since 2015.
Under the terms of the agreement, Pfizer will gain exclusive rights to distribute and commercialise the drug in Europe, including Austria, France, Germany, Italy and the UK, where it is already available.
In addition, Pfizer will be responsible for further European Cresemba launches expected throughout 2017 and 2018. Basilea will remain the marketing authorisation holder for this product in the EU.
This marks the latest addition to Pfizer's range of anti-infective medicines, which currently offers more than 80 products covering a wide range of conditions.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard